Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 22 at 2:00 PM EDT

Register Free →

This Solicitation opportunity from Government of Canada was posted on December 12, 2022. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Biomonitoring of Perfluoroalkyl Substances (PFAS) in biobanked plasma samples

Closed
1000246578Canada

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Government of Canada → Health CanadaView Agency

NAICS

N/A

Place of Performance

*National Capital Region (NCR), CAN

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed
Posted

Solicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyGovernment of Canada → Health Canada
Contacts1 person available
OfficeN/A
Organization / Agency
Government of Canada → Health Canada
View Agency Profile
Office AddressN/A
Contacts
Phillips WesleyPoint of Contact

Full Description

Show more
Perfluoroalkyl substances (PFAS) are a class of about 5000 chemicals commonly used for their heat, oil, water, and stain repellant properties in a wide range of consumer products including cookware, food packaging, and stain and water repellant fabrics. Data are limited on exposure levels and health effects in Canadians. PFAS do not break down easily, are widely found in the environment and in humans, and some have been found to have health impacts, including effects on the endocrine system.Identifying the levels of exposure to multiple PFAS and potential associations with effects on endocrine function would, therefore, address an important gap in scientific understanding and contribute to policy guidelines for these chemicals. The work described in the requirement will provide necessary data to address this gap by measuring 40 different PFAS in 2776 plasma biospecimens from the CARTaGENE biobank.